Notably, many approved or experimental targeted agents are precisely directed against these targets, for example, the PI3K inhibitors in BC, mTOR inhibitors in breast and kidney cancer, AKT inhibitors in BC, BRAF, and MEK inhibitors in melanoma or PARP inhibitors in several solid tumors.4,20-24 However, these drugs are costly, present with several side effects and are often administered without identification of the altered pathway of interest (eg, everolimus or capivasertib). The gene discussed is BRAF; the disease is melanoma.